<SEC-DOCUMENT>0001833141-26-000039.txt : 20260611
<SEC-HEADER>0001833141-26-000039.hdr.sgml : 20260611
<ACCEPTANCE-DATETIME>20260611143435
ACCESSION NUMBER:		0001833141-26-000039
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20260611
FILED AS OF DATE:		20260611
DATE AS OF CHANGE:		20260611

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CYBIN INC.
		CENTRAL INDEX KEY:			0001833141
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			A6
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40673
		FILM NUMBER:		261082628

	BUSINESS ADDRESS:	
		STREET 1:		100 KING STREET WEST
		STREET 2:		SUITE 5600
		CITY:			TORONTO
		STATE:			A6
		ZIP:			M5X 1C9
		BUSINESS PHONE:		(908) 764-8385

	MAIL ADDRESS:	
		STREET 1:		100 KING STREET WEST
		STREET 2:		SUITE 5600
		CITY:			TORONTO
		STATE:			A6
		ZIP:			M5X 1C9
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>cybininc-form6xk06x11x2026.htm
<DESCRIPTION>6-K
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="i55ca248ab65e498eaca96c8267aa7a86_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="-sec-extract:summary;margin-bottom:5pt;margin-top:5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">UNITED STATES<br>SECURITIES AND EXCHANGE COMMISSION</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"><br></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Washington, D.C. 20549</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"><br><br></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Form 6-K</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"><br><br></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16<br>UNDER THE SECURITIES EXCHANGE ACT OF 1934</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"><br></font></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">For the month of June, 2026.</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Commission File Number&#58; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">001-40673</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%"><br></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"><br></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Cybin Inc.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%"><br></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">(Exact Name of Registrant as Specified in Charter)<br><br></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">(Address of principal executive offices) </font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Form 20-F  </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:14pt;font-weight:400;line-height:115%">&#9633;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">  Form 40-F &#8864;</font></div><div><font><br></font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">SIGNATURE</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.<br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.038%"><tr><td style="width:1.0%"></td><td style="width:5.048%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.398%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.696%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.851%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.507%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">CYBIN INC.</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">(Registrant)</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">June 11, 2026</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.05pt;margin-top:0.05pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">&#47;s&#47; Greg Cavers&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"> </font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Name&#58;</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Greg Cavers</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Chief Financial Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%">  </font></div><div><font><br></font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline">EXHIBIT INDEX</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.980%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.820%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">99.1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="final-2026x06x11xhcwainwri.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">News Release dated June 11, 2026</a></font></div></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%"> </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>final-2026x06x11xhcwainwri.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="i8a7575b0b0ce461f920b8578248c2707_1"></div><div style="min-height:72pt;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div><div style="text-align:center"><img alt="image_0.jpg" src="image_0.jpg" style="height:101px;margin-bottom:5pt;vertical-align:text-bottom;width:206px"></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:133%">Helus Pharma to Participate in the H.C. Wainwright </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:133%">7</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.1pt;font-weight:700;line-height:133%;position:relative;top:-4.89pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:133%"> Annual Neuro Perspectives Conference</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">NEW YORK &#38; TORONTO </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#8211; June 11, 2026 &#8211; Helus Pharma</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:133%;position:relative;top:-3.85pt;vertical-align:baseline">TM </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">(Nasdaq&#58; HELP) (Cboe CA&#58; HELP), a clinical-stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists (&#8220;NSAs&#8221;), today announced that Amir Inamdar, Helus Pharma&#8217;s Chief Medical Officer, will participate in a fireside chat at the H.C. Wainwright 7</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:133%;position:relative;top:-3.85pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%"> Annual Neuro Perspectives Hybrid Conference taking place June 15-16, 2026. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">The fireside chat will be available on demand beginning on Monday, June 15 at 7&#58;00 a.m. EDT.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">To register for the webcast, </font><font style="color:#467886;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">click here</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">. A replay will be available on the </font><font style="color:#467886;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Events &#38; Presentations</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%"> page of Helus Pharma&#8217;s investor relations website. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">About Helus Pharma</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Helus Pharma&#8482;, the commercial operating name of Cybin Inc. (the &#8220;Company&#8221; or &#8220;Helus Pharma&#8221;) is a clinical stage pharmaceutical company committed to helping minds heal by developing proprietary NSAs - novel serotonergic agonists&#58; synthetic molecules designed to activate serotonin pathways that are believed to promote neuroplasticity. The Company&#8217;s proprietary NSAs are intended to address the large unmet need for people who suffer from depression, anxiety, and other mental health conditions.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">With class leading data, Helus Pharma aims to improve the treatment landscape through the introduction of NSAs that provide durable improvements in mental health. Helus Pharma is currently developing HLP003, a proprietary NSA, in Phase 3 clinical development for the adjunctive treatment of major depressive disorder that has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration and HLP004, also a proprietary NSA in Phase 2 for generalized anxiety disorder. Additionally, Helus Pharma has an extensive research portfolio of investigational NSAs. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">The Company operates in Canada, the United States, the United Kingdom, and Ireland.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">For Company updates and to learn more about Helus Pharma, visit </font><font style="color:#467886;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">www.helus.com</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%"> or follow the team on X, LinkedIn, YouTube and Instagram. Helus Pharma</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:133%;position:relative;top:-3.85pt;vertical-align:baseline">TM</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%"> is a trademark of Cybin Corp.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">Cautionary Notes and Forward-Looking Statements</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Certain statements in this news release relating to the Company are forward-looking statements or forward-looking information within the meaning of applicable securities laws (collectively, &#8220;forward-looking statements&#8221;) and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as &#8220;may&#8221;, &#8220;should&#8221;, &#8220;could&#8221;, &#8220;potential&#8221;, &#8220;possible&#8221;, &#8220;intend&#8221;, &#8220;estimate&#8221;, &#8220;plan&#8221;, &#8220;anticipate&#8221;, &#8220;expect&#8221;, &#8220;believe&#8221; or &#8220;continue&#8221;, or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the Company&#8217;s plans to engineer proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health conditions. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include&#58; fluctuations in general macroeconomic conditions&#59; fluctuations in securities markets&#59; expectations regarding the size of the NSA market&#59; the ability of the Company to successfully achieve its business objectives&#59; plans for growth&#59; political, social and environmental uncertainties&#59; employee relations&#59; the presence of laws and regulations that may impose restrictions in the markets where the Company operates&#59; implications of disease outbreaks on the Company's operations&#59; and the risk factors set out in each of the Company's management's discussion and analysis for the three and nine month periods ended December 31, 2025, and the Company&#8217;s annual information form for the year ended March 31, 2025, which are available under the Company's profile on SEDAR+ at </font><font style="color:#467886;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">www.sedarplus.ca</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%"> and with the U.S. Securities and Exchange Commission on EDGAR at </font><font style="color:#467886;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">www.sec.gov&#47;edgar</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">The Company makes no medical, treatment or health benefit claims about the Company&#8217;s proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding NSAs or HLP003, HLP004 and other programs of the Company. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of NSAs, HLP003, HLP004 or other programs of the Company can diagnose, treat, cure or prevent any disease or condition. Rigorous scientific research and clinical trials are needed. If Helus Pharma cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on the Company&#8217;s performance and operations.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:133%">Neither Cboe Canada, nor the Nasdaq Global Market stock exchange, have approved or disapproved the contents of this news release and are not responsible for the adequacy and accuracy of the contents herein. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">Investor Contact&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Matthew Beck</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">astr partners</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Managing Partner</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">(917) 415-1750</font></div><div style="text-align:justify"><font style="color:#467886;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Matthew.beck&#64;astrpartners.com</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">George Tziras</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Chief Business Officer</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Helus Pharma</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1-866-292-4601</font></div><div style="text-align:justify"><font style="color:#467886;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">irteam&#64;helus.com</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%"> &#8211; or &#8211; </font><font style="color:#467886;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">media&#64;helus.com</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%"> </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">Media Contact&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Johnny Tokarczyk</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">RXMD</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Public Relations Director</font></div><div style="text-align:justify"><font style="color:#467886;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">jtokarczyk&#64;rxmedyn.com</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%"> </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">(914) 772-7562</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_0.jpg
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M:X1#K0>Z6%YI:XW\.DQ'OUIPO.1SP0>.KESS\+&\P!_%#WLV@40S#[>GT4/
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MT_G,[?74ERA1BVRMND" C:12GZG%W!-X*R VH8MF%QSYL^[/K\52O)V'P%E
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M(P:HQ7/-6:H"O=RL?TO"Q2C:WU=$D4&AQ,KF]2M6K,@R$9F4P0QF4O\PNH2
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M^1FDAR&9"4P.:!T-&\R,OB&T,*DL4O3AUA/A1FYVFWBZ>[)7F%X!B%]%;[L
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M 8NL54R?O?J!$^</;IW%8+'YK;-//';3K#T>H0V.DA<[W@A,3OL9)34#T?9
M6=>)TMGWNJY["3&/_/$%18J$BI32[Z@1BI%:R6N'"WSLWL2.^)$&LC.:)XPP
M,1<KD8#/<M].-4,L0R>,NYXC'@)O+ 0R3FH8\+*KCIRHK[ )S\2^ 3@U9.@
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M\$CMK$/N&?00\! 82P3^/P   /__,6Q,K     9)1$%4 P!OT^$\,N*Y>
*  !)14Y$KD)@@@$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
